Nine-Year Consecutive Attendance, Ten-Year Commitment Ahead: Bayer Delivers a New CIIE Outcome with “Breakthrough Technologies” and More Than a Dozen Partnership Signings

Shanghai, November 10, 2026 — The 9th China International Import Expo (CIIE) has come to a close. Attending for the ninth consecutive year, Bayer once again showcased its Pharmaceuticals (with Radiology), Consumer Health, and Crop Science divisions, bringing nearly 30 debut exhibits in healthcare and modern agriculture. Bayer also held and took part in 60 signing ceremonies, achievement releases and exchange events centered on access to innovative medicines, clinical research, healthcare data and AI, primary care, evidence-based science and market access and signed more than 10 partnership agreements. Meanwhile, Bayer has already signed up in advance for the 10th CIIE, moving from nine consecutive editions toward ten years of “perfect attendance.”

Bayer signed up for the 10th CIIE in advance

Xiaolan Zhou, Executive Vice President, Pharmaceuticals Division, Bayer AG/ President of Bayer Pharmaceuticals China, President of Bayer China, said: “After nine consecutive years at the CIIE, we are more convinced than ever of the unique value of this platform. It is not only a window into the latest innovations, but also an important bridge connecting global opportunities with China’s development, bringing partners together and turning innovative ideas into real-world impact. Bayer has participated in the CIIE every year since its inception and has also benefited greatly from the opportunities it creates. Over the years, we have seen innovations move from exhibition showcases to the market, and initial agreements grow into long-term partnerships. We have also witnessed first-hand the growing strength and dynamism of China’s innovation ecosystem. At this year’s CIIE, guided by our mission ‘Health for all, Hunger for none,’ Bayer once again brought together our Pharmaceuticals, Consumer Health and Crop Science businesses. From addressing major disease challenges and improving everyday health to advancing agricultural innovation and sustainability, one thing is increasingly clear to us: China is not only one of the world’s largest and most dynamic markets, but is also emerging as an increasingly important source of innovation for the world. Looking ahead, we will continue to leverage the CIIE as a platform for openness and collaboration, bringing global innovation closer to the needs of the Chinese market while building stronger connections between China’s innovation ecosystem and the rest of the world. Our ambition is to not only bring more global innovations to China faster, but also help more Chinese innovations reach the world.”

From a “Nine-Year Date” to a “Ten-Year Pledge”: A Long-Term Commitment Delivered on the CIIE Stage

Bayer receives the CIIE’s “Nine-Time Perfect Attendance” recognition

Over nine years, “perfect attendance” has become a defining mark of how Bayer and the CIIE have grown together. This year, Bayer exhibited for the ninth consecutive time and received the CIIE’s “Nine-Time Perfect Attendance” honor, and signed up for the 10th CIIE in advance, moving toward a full ten years of perfect attendance.

Behind this continuity is a more concrete CIIE “report card.” As of the 9th CIIE, Bayer has brought a cumulative total of 98 debut exhibits, helped land 24 “CIIE babies,” held and participated in nearly 200 events inside and outside its booth, and reached more than 60 landmark signings.

Over these nine years, the way Bayer takes part in the CIIE has also evolved. When Bayer first exhibited in 2018, the CIIE was mainly a window for global innovation to accelerate its entry into China. Today, from the launch of innovative products, to local innovation partnerships, to clinical data, research capabilities and innovation outcomes from China contributing to broader R&D and innovation, Bayer’s collaboration with the Chinese market continues to deepen.

Nine editions of “perfect attendance” mark a long-term commitment, and signing up early for the 10th CIIE opens the next chapter. In 2027, Bayer will also mark its 145th anniversary in China. From a “nine-year date” to a “ten-year pledge,” continued participation in the CIIE has become a microcosm of Bayer’s long-term commitment to China and its participation in China’s innovation-driven development.

From “First Showcase” to “First Launch”: Cutting-Edge Innovation Moves Faster Toward Real-World Application

At this CIIE, more than 480 representative exhibits made global, Asian or China debuts, a record high¹. The “value” of these debuts lies not only in how new the technology is, but also in whether cutting-edge innovation can respond to real needs and move faster into practical use.

Among Bayer’s nearly 30 debut exhibits, Sunharbo (asundexian tablets), a newly approved, first-in-class medicine for the prevention of recurrent stroke, became one of the most closely watched innovations. It was selected as one of the “Top 10 Breakthrough Technologies” in the report Powering the Future: Report on Cutting-Edge and Hard-Tech Exhibits at the 9th CIIE, and was featured on CCTV’s “CIIE New Products Showcase” program, reflecting how quickly frontier scientific innovation is moving toward real-world application.

In addition, new indications of innovative medicines including Kerendia (finerenone tablets), Nubeqa (darolutamide tablets), Hyrnuo (sevabertinib tablets) and Eylea 8mg (aflibercept 8 mg, 114.3mg/ml solution for injection) made their first appearance at the CIIE. Gadoquatrane Injection, a third-generation novel gadolinium-based contrast agent with a tetrameric structure, made its China debut, and the MEDRAD Mark 7 Arterion high-pressure injection system made its CIIE debut following localization.

The same translation of innovation into impact is under way in Consumer Health and Crop Science. At this CIIE, Bayer Consumer Health brought seven global debuts, addressing the increasingly diverse health needs of Chinese consumers across scenarios including teen scalp care, babie skin care, maternal and babies health, and nutritional supplementation. In agriculture, Bayer Crop Science brought eight China debuts and six CIIE debuts, spanning its three core businesses of crop protection, corn seeds and vegetable seeds. These innovations, developed to meet real needs in China, will move beyond the CIIE into hospitals, pharmacies and fields, creating value for patients, consumers and growers.

From “Individual Partnerships” to “Whole-Course Management”: China’s Role in Global Innovation Keeps Deepening

If the shift from “first showcase” to “first launch” reflects the speed at which innovation lands, the research outcomes and innovation partnerships released this year show another, more pronounced change: China is not only an application market for global innovation, but is also increasingly involved in innovation itself.

During the CIIE, Bayer held dozens of signing ceremonies, achievement releases and exchange events, with partners spanning government, healthcare, research institutions and industry associations. A series of collaborations has extended from single products and one-off projects toward scientific evidence, clinical practice, whole-course management, primary-care services and industry synergy.

At the source of innovation, China’s participation in global innovation is deepening. For Sunharbo, Bayer further presented during the CIIE the contribution of Chinese patients and investigators to the global Phase III study, together with data from the Chinese population, highlighting the role of Chinese evidence in global R&D.

Data and artificial intelligence are also moving further into clinical innovation. Bayer and the Eye Hospital of Wenzhou Medical University formally signed a letter of intent on data collaboration. The two parties will focus on the compliant circulation and innovative application of high-quality healthcare data on retinal diseases, leveraging their respective strengths in clinical research and pharmaceutical innovation to explore new paths for data-driven ophthalmic research and innovation.

Collaboration is also extending from innovative R&D to whole-course disease management and stronger primary-care capabilities. Bayer signed a strategic partnership with the China Stroke Specialty Alliance. The two parties will deepen collaboration on whole-course management of stroke recurrence prevention and jointly advance the full “prevention, treatment, management and rehabilitation” chain for stroke. The “2026 Prostate Cancer Quality Control Excellence Enhancement Program,” hosted by the Beijing Hongyuan Charity Foundation and supported by Bayer, was also formally signed at this CIIE. Aligned with the Healthy China requirements for standardized cancer diagnosis and treatment, the program is dedicated to strengthening the prostate cancer quality-control system and narrowing regional differences in care. With Bayer’s support, the China Health Promotion Foundation for Human Health Science and Technology, together with heart failure experts and patient representatives, formally launched the Heart Failure Care Public Awareness Ambassador Initiative. The initiative focuses on the risk of sudden cardiac death that “stable” heart failure patients still face, aiming to promote standardized treatment and long-term management so that patients can live longer and better. Bayer also formally launched the Proteinuria Target Initiative. The event brought together leading experts in nephrology, cardiovascular medicine and endocrinology, public-interest organizations and company representatives to explore new pathways for standardized proteinuria management in people with diabetes.

Bayer holds a celebration for the approval of Sunharbo (asundexian tablets) and signs a strategic partnership with the China Stroke Specialty Alliance

In consumer health, Bayer reached multiple collaborations around evidence-based science and channel reach to bring innovative health solutions into consumers’ daily lives faster. Against a market backdrop shifting from “marketing-driven” to “evidence-driven” and from “ingredient stacking” to “science-based evidence,” Bayer and Sirio Health established the “Bayer–Sirio Health Joint Laboratory Evidence-Based Research Platform” at this CIIE, formally announcing deeper collaboration in nutrition and health science research and innovation translation. The joint laboratory will combine Bayer’s strengths in brand, products and consumer insights with Sirio Health’s capabilities in evidence-based research, R&D validation and innovation translation, creating an innovation-enabling platform that links scientific discovery, evidence-based validation and commercial rollout. Leveraging CIIE as a platform, Bayer brought together industry associations, academia and industry partners to participate in and support two thematic forums focused on innovation and development in the OTC and consumer health sectors, fostering industry consensus and dialogue on the sector’s future.

Signing and unveiling ceremony of the Bayer–Sirio Health Joint Laboratory Evidence-Based Research Platform

In agriculture, DEKALB, Bayer’s corn seed brand, brought the DEKALB Learning Center for its debut at the CIIE. Drawing on its variety portfolio and field experience, DEKALB has partnered with local channel partners and large-scale growers to establish more than 10 learning centers in China’s spring corn regions. Combining field demonstrations, technical training and knowledge sharing, the centers promote the adoption of quality varieties and science-based farming practices in more fields. To date, the learning centers have reached more than 5,000 people offline and generated over 100 million online views. Going forward, DEKALB will expand the learning centers into more corn-growing regions, combining good agronomic practices with quality seeds to unlock varietal potential and support higher grain yields and China’s efforts to strengthen food security through agricultural technology.

DEKALB Learning Center

From Chinese clinical data contributing to innovative R&D, to hospitals and research institutions jointly building real-world evidence; from disease treatment to whole-course management; and from health services to agricultural technology reaching further down to the grassroots, the partnerships at this CIIE go beyond signing agreements. They continue to move forward in step with the real needs of patients, consumers and growers.

As the 9th CIIE comes to a close, Bayer has already reserved its “ticket” to the next edition. From nine years of “perfect attendance” toward a ten-year pledge, from “first showcase” moving faster toward “first launch,” and from showcasing innovation to co-innovating, what the CIIE records is not only the process of innovations moving from the booth to the real world, but also the solid steps Bayer has taken in putting down roots and moving forward in China.

1 新高有新意：进博会首发首展首秀产品超480件》：https://kolkata.mofcom.gov.cn/zhxx/art/2026/art_2144ad8b5d2644ce890909abe9552d95.html

About Bayer
Bayer is a multinational enterprise with core competencies in the life science fields of healthcare and agriculture. In line with its mission, “Health for all, hunger for none,” the company aims to help tackle the major challenges arising from a growing and aging global population through its products and services, benefiting both people and the planet and supporting prosperity. Bayer is committed to driving sustainable development and generating a positive impact through its business. At the same time, the Group aims to enhance its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2025, the Group employed approximately 88,000 people and had sales of 45.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the company’s actual future results, financial situation, development, or performance and the estimates given here. These factors are discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. Bayer assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer is a holding company with subsidiaries operating on a global scale. The terms “Bayer” or “Company” as used herein may refer to one or more subsidiaries, as the context requires.